Please click on the link just before the start of the webinar
This presentation will discuss the current outcomes and future challenges of the H2Seq Initiative, an Australian government-funded initiative led by the Kirby Institute. H2Seq has a national collaborative network that aims to develop, implement, and evaluate platforms for HIV and hepatitis C (HCV) pathogen genomics for ‘near real time’ molecular epidemiology. Integrated with this is the development of a full-length genome next-generation sequencing protocol for diagnostic use for both HIV and HCV.
Professor Anthony Kelleher
Professor Anthony (Tony) Kelleher is a clinician scientist and director of the Kirby Institute at UNSW Sydney. He is also head of its Immunovirology and Pathogenesis Program, and principal of the Infection, Immunology and Inflammation Theme at UNSW Medicine and Triple-I Clinical academic group of the Advanced Health Research and Translation Centre (AHRTC) SPHERE. Read more..
Professor Andrew Lloyd
Professor Andrew Lloyd is an infectious diseases physician and immunovirology researcher in the Kirby Institute at the University of NSW where he leads the Viral Immunology Systems Program. He is an NHMRC Practitioner Research Fellow. His research team is studying hepatitis C, including clinical and epidemiological studies focused on people in prison, and laboratory-based studies of the host immune response which confers potentially protective immunity against hepatitis C. Professor Lloyd was previously awarded an Australia Medal (AM) for his work in establishing hepatitis services in the New South Wales prisons and for his research achievements in infectious diseases.
Opinions expressed by individuals at this event are solely of those of the individual/s and do not necessarily represent the views or opinions of the Kirby Institute or UNSW.